• "Right now the only thing slowing us down is money."

-George Colberg, founder and chairman of Kalos Therapeutics Inc., on the frustrations of venture fundraising

• "The p-value is convenient . . . but by itself, it doesn't tell the whole story."

-Richard Bittman, president of Bittman Biostat Inc., on the shortcomings of statistical standards

• "Unmet needs never hurt when you're trying to do novel things."

-David Apelian, chief medical officer for GlobeImmune Inc., talking about adaptive trial design in his company's Phase II prostate cancer trial

• "Like any game, you have to have the rules before you start playing."

-George Howard, biostatistics chair at the University of Alabama's School of Public Health, on the need to prospectively agree on adaptive trial designs